title: Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report.
abstract: A young woman presenting with an ovarian immature teratoma (stage IA, grade 2) demonstrates the dilemma associated with the decision to withhold adjuvant chemotherapy of documented clinical utility in a setting where highly effective treatment is available should the cancer ultimately recur.
authors.affiliation: University of Texas, M.D. Anderson Cancer Center, Houston, Tex., USA.
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman